Bispecific antibody treatment for the simultaneous activation of
immune and anti-cancer cells

AM105 is a bispecific antibody derived from the AffiMab platform that specifically targets
EGFR disease protein and immune cells.

  • AM105
  • AM105 possesses a dual mechanism of action designed for tumor treatment.
    Its primary target is the CD137 (4-1BB) surface protein found on immune cells,
    while its secondary target is the EGFR disease protein. Notably, AM105 aims to
    mitigate toxicity by selectively activating immune cells in the vicinity of tumors.
    Additionally, its versatility allows for straightforward adaptation to address
    various cancers by substituting the target disease protein.
Designed by CHAIRONE
© AbClon. All rights reserved.